FDA Approves LEQEMBI® IQLIKTM (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s DiseaseLEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatment of 18 months
LEQEMBI IQLIK will be launched on October 6, 2025, in the U.S.